GlassScriptPhysician profile
Mary Camille Chelf
NPI 1821617077
$7,134.60
in general payments reported to CMS, 2019-2025
30 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $593 · 2023: $1,293 · 2024: $2,605 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,528 · Education: $14.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,527.64 |
| Education | $14.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,885.00 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $950.03 | 2022-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $910.20 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $688.85 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $420.41 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $297.49 | 2023-2025 | |
| Genzyme Corporation | $294.06 | 2023-2025 | |
| Madrigal Pharmaceuticals | $252.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $227.46 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $177.74 | 2023-2025 | Linzess |
| Aimmune Therapeutics, INC. | $165.54 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $159.52 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $132.13 | 2022-2025 | Sucraid, Sucraid |
| Biocon Biologics INC | $97.92 | 2025 | Yesintek |
| Phathom Pharmaceuticals, INC. | $63.36 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $45.42 | 2024-2025 | Terlivaz |
| Celgene Corporation | $44.97 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $42.52 | 2025 | |
| Celltrion USA INC. | $41.20 | 2023-2025 | Vegzelma, Yuflyma |
| Amgen INC. | $30.59 | 2023 | Avsola, Amjevita |
| Pfizer INC. | $27.45 | 2022 | |
| Merck Sharp & Dohme LLC | $26.06 | 2023-2024 | Dificid |
| Daiichi Sankyo INC. | $25.71 | 2023 | Injectafer |
| Eton Pharmaceuticals, INC. | $24.72 | 2025 | Galzin, Betaine Anhydrous, Nitisinone |
| Medtronic, INC. | $23.57 | 2024 | Interstim |
| Orphalan INC | $20.91 | 2025 | Cuvrior |
| Pharmacosmos Therapeutics INC. | $16.61 | 2022 | |
| Ardelyx, INC. | $14.34 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $14.06 | 2023 | |
| Fresenius Kabi USA, LLC | $13.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Chelf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.